CLDF Title
Home | Contact Us | Bookmark
HBV HE HCC HCV
About CLDF Centers of Educational Expertise  
CME Dinner Meetings Webcasts Slide Library Abstract Library Conference Highlights
 
Back  
 
Reuters Health Information (2009-10-01): "Substantial" toxicity with peginterferon use: FDA staff

Clinical

"Substantial" toxicity with peginterferon use: FDA staff

Last Updated: 2009-10-01 19:30:14 -0400 (Reuters Health)

WASHINGTON (Reuters) - Schering-Plough Corp's injectable drug PegIntron (peginterferon) carries "substantial toxicity" and had no effect on overall survival in melanoma skin cancer patients undergoing surgery, U.S. Food and Drug Administration staff reviewers said in documents released on Thursday.

Schering is seeking FDA approval to sell PegIntron for use with surgery in cases where the melanoma has spread to the lymph nodes.

PegIntron is already approved for liver disease in conjunction with the company's Rebetol (ribavirin) for chronic hepatitis C.

The FDA released the documents ahead of an advisory committee meeting on Monday to discuss whether to approve the drug. The agency usually takes the advice of its outside experts.

 
 
 
 
                 
 
HBV
Webcasts
Slide Library
Abstract Library
 
HE
CME Dinner Meeting
Webcasts
Slide Library
Abstract Library
 
HCC
Slide Library
Abstract Library
 
 
HCV
Webcasts
Slide Library
Abstract Library
 
CLDF Follow Us
   
 
About CLDF
Mission Statement
Board of Trustees
Board of Advisors
CLDF Supporters
 
Other Resources
Liver News Library
Journal Abstracts
Hep C Link to Care
 
Centers of
Educational Expertise
Regional Map
     
   
  The Chronic Liver Disease Foundation is a non-profit organization with content developed specifically for healthcare professionals.
© Copyright 2012-2014 Chronic Liver Disease Foundation. All rights reserved. This site is maintained as an educational resource for US healthcare providers only.
Use of this Web site is governed by the Chronic Liver Disease Foundation terms of use and privacy statement.